BioCentury | Nov 26, 2018
Distillery Techniques

Drug delivery

TECHNOLOGY: Peptides; polymers An amphiphilic dendrimer-peptide construct could be used for tumor-targeted delivery of siRNA therapies. The construct has four components: an amphiphilic dendrimer complex for loading with siRNA cargo; a peptide composed of repeating...
BioCentury | Feb 8, 2017
Distillery Therapeutics


INDICATION: Nerve damage Mouse studies suggest CRYAB could help treat peripheral nerve damage. In a mouse model of sciatic nerve damage, human CRYAB increased remyelination of the sciatic nerve and mechanical sensitivity and decreased gait...
BioCentury | Sep 29, 2016
Distillery Techniques

Techniques: Panel of 12 hippocampal proteins to diagnose early stage Alzheimer's disease

Biomarkers TECHNOLOGY: Tissue markers Hippocampal expression of a panel of 12 proteins could help diagnose early stage AD. Microarray analyses of postmortem brain tissue samples from six individuals previously not diagnosed with AD identified associations...
BioCentury | Nov 12, 2015
Distillery Therapeutics

Therapeutics: Crystallin α B (CRYAB; HSPB5)

Ophthalmic disease In vitro, mouse and patient sample studies suggest a chaperone of CRYAB could help treat cataract. A differential scanning fluorometry-based screen on a small molecule library identified a lead compound that decreased formation...
BioCentury | Nov 12, 2015
Product R&D

Crystallin-clear ViewPoint

By exploring the biophysics of proteins with disease-associated mutations, a UCSF group has developed a way to screen for drugs that rescue the activity of non-enzymatic targets, and proved its value with molecular chaperones. After...
BioCentury | Aug 13, 2015
Distillery Therapeutics

Therapeutics: Crystallin α A (CRYAA; HSPB4); lanosterol synthase (LSS)

Ophthalmic disease INDICATION: Cataract In vitro and dog studies suggest the steroid precursor lanosterol could help treat cataracts caused by aggregation of CRYAA and other crystallin proteins in lens fibers. In human lens progenitor cells...
BioCentury | Jan 17, 2013
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Parkinson's disease (PD) Dopamine D2 receptor In vitro and mouse studies suggest dopamine D2 receptor agonists could help treat neuroinflammation in diseases such as PD....
BioCentury | Aug 16, 2012
Targets & Mechanisms

Amyloids for inflammation

Researchers at Stanford University have found that systemic treatment with b-amyloid peptides can reduce inflammation and reverse paralysis in mouse models of multiple sclerosis. 1 Cardinal Therapeutics Inc. has licensed the work and now is...
BioCentury | Mar 1, 2012
Distillery Therapeutics

Indication: Inflammation

Indication Target/marker/pathway Summary Licensing status Publication and contact information Inflammation Inflammation Crystallin aB (CRYAB; HSPB5) In vitro studies identified a mechanism for HSPB5's anti-inflammatory activity that could help improve treatment of multiple sclerosis (MS). HspB5...
BioCentury | Aug 4, 2011
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Neurology Neuropathy Histone deacetylase 6 (HDAC6); heat shock 27 kDa protein 1 (Hspb1; Hsp27); tubulin Mouse studies suggest HDAC6 inhibitors could help treat Charcot-Marie-Tooth (CMT)...
Items per page:
1 - 10 of 12